[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"amci---amnestic-mild-cognitive-impairment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:amci---amnestic-mild-cognitive-impairment":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100460970","phase-2-targeting-cognition-in-early-alzheimers-disease-by-improving-sleep-with-trazodone-100460970",false,"NCT05282550","Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone","RCT Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone (REST)","REST","Inclusion Criteria:\n\n1. Mild Cognitive Impairment (MCI) as defined by Albert et al.2 including subjective memory complaint and\u002For objective evidence of memory problems;\n2. Clinical Dementia Rating (CDR) of 0.5 with a Memory Box score of \\>=0.5;\n3. Evidence of sleep complaints with Pittsburgh Sleep Quality Index score of \\>5 (a well-validated cutoff observed in \\>40% of older persons);\n4. Memory performance \\> 1.5 Standard Deviation (SD) below age-and education-matched control subjects on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) List Recall;\n5. Visual and auditory acuity adequate for neuropsychological testing;\n6. Good general health with no disease expected to interfere with the study;\n7. Able to have Magnetic Resonance Imaging (MRI) scan;\n8. Availability of knowledgeable informant (KI)\n9. Buschke Selective Reminding Test or more standard deviations below age-education norms\n\nExclusion Criteria:\n\n1. Less than 55 years of age to reduce likelihood of including individuals with frontotemporal dementia or non-dementia MCI;\n2. Too frail or medically unstable to undergo study procedures;\n3. Prior diagnosis of Obstructive Sleep Apnea (OSA) or evidence of moderate-to-severe OSA on baseline Home Sleep Test (HST) as evidenced by an apnea\u002Fhypopnea index of \\>15;\n4. Dementia;\n5. Cognitive complaints and deficits better explained by other medical\u002Fneurologic conditions;\n6. Delirium;\n7. Allergic to trazodone;\n8. Taking sleep medications including trazodone;\n9. Current substance abuse;\n10. Current major depressive, manic, or acute psychotic episode;\n11. Prior diagnosis of significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol or represent alternate primary cause of memory problems beyond Alzheimer's Disease (AD) pathology:\n12. Lack of available KI;\n13. Prior diagnosis of Q wave T wave Corrected for heart rate (QTc) \\> 470 msec (females) or \\> 450 msec (males);\n14. Inability to provide informed consent","ALL","55 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","To investigate the effect of trazodone on sleep, hippocampal-dependent memory and hippocampal excitability. The investigators hypothesize that trazodone will improve total sleep time and proportion of time in Slow Wave Sleep (SWS).",[27,28],"AMCI - Amnestic Mild Cognitive Impairment","Sleep Disturbance",[30,31,32,33],"AMCI","Slow wave sleep","Trazodone","Cognition","RECRUITING","2026-06-15",{"date":37,"type":38},"2026-06-17","ACTUAL",{"date":40,"type":38},"2023-02-02",{"date":42,"type":21},"2028-06-30",{"name":44,"class":45},"Johns Hopkins University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":57,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":46},"100613916","neurocognitive-assessment-platform-4-alzheimer-100613916","NCT07272811","Neurocognitive Assessment Platform 4 Alzheimer","NAP4A2020","Inclusion criteria common to both experimental groups:\n\n* Signature of informed consent\n* Age between 55 and 80 years\n* Absence of functional impact on daily living activities or minimal impact on instrumental activities\n\nSpecfic inclusion criteria for Healthy Controls recruitment:\n\n* Normal global cognitive efficiency (Mini Mental State Examination scores of 28 or higher)\n* Absence of specific cognitive deficits (memory and other cognitive domains) that are abnormal for age, sex, and education level (1.5 standard deviations below the mean for age- and education-matched controls), as assessed by objective, standardized cognitive tests.\n\nSpecific inclusion criteria for aMCI recruitment:\n\n* Cognitive difficulties reported by the individual, their family member, or their primary care physician\n* Normal global cognitive efficiency (Mini Mental State Examination score within 0.5 standard deviations of the average for age- and education-matched control subjects).\n* Specific cognitive deficits related to memory or multi-domain cognitive impairments (involving memory and other cognitive domains) that are atypical for the individual's age (1.5 standard deviations below the average for age- and education-matched controls), as determined by objective, standardized cognitive tests.\n\nExclusion Criteria:\n\n* Rejection of informed consent\n* Important sensory deficits (e.g., hearing loss or hypovisus)\n* Current or previous history of psychiatric illness\n* Current or previous degenerative pathology of the central nervous system (CNS)\n* Presence of systemic diseases in anamnesis\n* Presence of cerebrovascular events in anamnesis\n* Use of alcohol or psychotropic substances in anamnesis",true,"80 Years",{"count":20,"type":21},"12 Months","OBSERVATIONAL","The aging population in Europe is leading to an increase in neurodegenerative diseases, such as Alzheimer's disease (AD), which is expected to affect 152 million people worldwide by 2050. In Italy, there are approximately 1.2 million cases of dementia, with 600,000 attributed to AD. Given the limited effectiveness of current pharmacological treatments, there is a growing need for early, non-pharmacological interventions to slow disease progression and improve the quality of life for patients and caregivers.\n\nThe Neurocognitive Assessment Platform 4 Alzheimer (NAP4A) study aims to create a digital platform for the early detection of amnestic mild cognitive impairment (MCIa), considered an intermediate stage between normal aging and dementia. The platform uses non-invasive biometric tools, including EEG, blood flow sensors, and eye-tracking devices, to collect neurophysiological and behavioral data.\n\nThe study will involve 100 participants aged 55 to 80, divided into two groups: one with individuals diagnosed with MCIa and a control group of healthy participants. Over 12 months, regular assessments will be conducted to identify markers that predict the progression from MCIa to AD. The goal is to develop advanced diagnostic tools that support early and targeted interventions.",[61,62,27,63],"MCI","MCI Conversion to Dementia","Alzheimer Disease","2026-01-20",{"date":66,"type":38},"2026-01-22",{"date":68,"type":38},"2021-12-15",{"date":70,"type":21},"2026-06",{"name":72,"class":45},"IRCCS San Raffaele",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100615048","effects-of-photobiomodularion-on-brain-connectivity-and-cognitive-function-in-cognitive-impairment-100615048","NCT07287527","Effects of Photobiomodularion on Brain Connectivity and Cognitive Function in Cognitive Impairment","The Effects of Transcranial Photobiomodulation (t-PBM) on Cognitive Performance and Functional Brain Connectivity in Patients With Mild Cognitive Impairment and the Role of Genetic Factors","PBM-CogConnect","Inclusion Criteria:\n\n* Age 55 years or older\n* Diagnosis of amnestic Mild Cognitive Impairment (aMCI)\n\nExclusion Criteria:\n\n* Presence of a neurological disorder\n* Presence of a severe psychiatric disorder\n* Having a pacemaker or other implanted medical device that is not MRI-compatible",{"count":82,"type":21},60,[84],"NA","The goal of this clinical trial is to learn if transcranial photobiomodulation (t-PBM), a light-based brain therapy, can help improve memory and cognitive skills in older adults with amnestic mild cognitive impairment (aMCI). This condition involves memory problems that are greater than normal aging and may increase the chance of developing Alzheimer's disease.\n\nThe main questions this study aims to answer are:\n\n1. Does t-PBM, when used together with cognitive training, improve memory and cognitive skills?\n2. Does t-PBM change how certain brain areas communicate with each other, especially in the default mode network (DMN)?\n\nResearchers will compare:\n\nt-PBM plus cognitive training to sham (inactive) t-PBM plus the same cognitive training to see if the active light treatment leads to better cognitive improvement and healthier brain activity.\n\nParticipants will:\n\n* Provide a blood sample so the research team can create a genetic profile;\n* Complete cognitive tests before and after the 4-week program;\n* Meet with a dietitian before and after the program so the research team can make sure diet stays consistent and does not influence brain results;\n* Have a brain fMRI scan before and after treatment to measure brain connectivity changes;\n* Take part in eight sessions of cognitive training;\n* Receive either active t-PBM or sham t-PBM during these sessions.",[27],[88,89,90,91,92,93,94],"t-PBM","aMCI","fMRI","Cognitive Rehabilitation","functional connectivity","APOE","COMT","2025-12-13",{"date":97,"type":38},"2025-12-17",{"date":99,"type":38},"2024-03-30",{"date":101,"type":21},"2026-10",{"name":103,"class":45},"Uskudar University",2]